In the whole population of 60 enrolled patients, the overall response rate was 53% with a CR rate of 38%, of which 78% were MRD negative; 21% of the NPM1-mut AML patients displayed a complete response, with 100% MRD negativity in this responding population [119]. The gene discussed is NPM1; the disease is acute myeloid leukemia.